April 18, 2026
4 scientific posters at AAN 2026
Chicago, April 18-22, 2026 — Ad Scientiam was present at the annual congress of the American Academy of Neurology (AAN), the world's largest neurology gathering. Represented by Matthieu Lamy, President, and Clarissa Gorin, Director of Medical Affairs and Market Access Innovation, the team presented 4 scientific posters illustrating the contribution of our digital biomarkers for clinical monitoring and research in multiple sclerosis (MS) and generalized autoimmune myasthenia (gMG).
Multiple Sclerosis: integrating MSCopilot® into clinical practice
MS-FLOWER Poster — Identifying challenges to MSCopilot®'s integration into Multiple Sclerosis standard clinical practice
Session P5 · Poster 002 · Monday April 20, 11:45am-12:45pm CT
MS-FLOWER is our multicenter pilot study conducted in the United States. Its objective: to evaluate, in real-world conditions, the feasibility and conditions for integrating MSCopilot® into the standard MS care pathway.
MS-DETECT Poster — Real-world Digital Biomarkers Associated With Their Clinical Counterparts
Session P4 · Poster 004 · Monday April 20, 8-9am CT
MS-DETECT is an international multicenter clinical study aimed at validating the ability of MSCopilot® Detect to detect early disability progression in MS.
Generalized Autoimmune Myasthenia: validating ME&MG™ as a new monitoring standard
DOMYA Poster — Validation of ME&MG™ digital biomarkers in monitoring generalized Myasthenia Gravis symptoms
Session P9 · Poster 017 · Tuesday April 21, 5-6pm CT
The DOMYA study, conducted in France and the United States, is our pivotal clinical trial validating ME&MG™, a digital medical device dedicated to remote monitoring of patients living with gMG.
ME&MG™ Poster — Digital biomarkers correlate with equivalent MG-ADL and MG-QoL15r sub-items scores
Session P9 · Poster 015 · Tuesday April 21, 5-6pm CT
This second gMG poster deepens the item-by-item analysis of the correlation between our digital biomarkers and validated clinical scores.